225 related articles for article (PubMed ID: 22252523)
1. Antiproliferative effects of selective cyclooxygenase-2 inhibitor modulated by nimotuzumab in estrogen-dependent breast cancer cells.
Wang YX; Gao JX; Wang XY; Zhang L; Liu CM
Tumour Biol; 2012 Aug; 33(4):957-66. PubMed ID: 22252523
[TBL] [Abstract][Full Text] [Related]
2. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells.
Huang J; Yuan X; Pang Q; Zhang H; Yu J; Yang B; Zhou L; Zhang F; Liu F
Drug Des Devel Ther; 2018; 12():2223-2231. PubMed ID: 30038488
[TBL] [Abstract][Full Text] [Related]
4. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Shin DM; Zhang H; Saba NF; Chen AY; Nannapaneni S; Amin AR; Müller S; Lewis M; Sica G; Kono S; Brandes JC; Grist WJ; Moreno-Williams R; Beitler JJ; Thomas SM; Chen Z; Shin HJ; Grandis JR; Khuri FR; Chen ZG
Clin Cancer Res; 2013 Mar; 19(5):1244-56. PubMed ID: 23422093
[TBL] [Abstract][Full Text] [Related]
6. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells.
Jeon YW; Suh YJ
Oncol Rep; 2013 Feb; 29(2):819-25. PubMed ID: 23229294
[TBL] [Abstract][Full Text] [Related]
7. BC-N102 suppress breast cancer tumorigenesis by interfering with cell cycle regulatory proteins and hormonal signaling, and induction of time-course arrest of cell cycle at G1/G0 phase.
Lawal B; Kuo YC; Wu ATH; Huang HS
Int J Biol Sci; 2021; 17(12):3224-3238. PubMed ID: 34421361
[TBL] [Abstract][Full Text] [Related]
8. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.
Xiao H; Zhang Q; Lin Y; Reddy BS; Yang CS
Int J Cancer; 2008 May; 122(9):2115-24. PubMed ID: 18172863
[TBL] [Abstract][Full Text] [Related]
9. ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.
Liu J; Wu J; Zhou L; Pan C; Zhou Y; Du W; Chen JM; Zhu X; Shen J; Chen S; Liu RY; Huang W
Oncotarget; 2015 Aug; 6(25):21341-52. PubMed ID: 26050198
[TBL] [Abstract][Full Text] [Related]
10. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Chen L; He Y; Huang H; Liao H; Wei W
Med Oncol; 2008; 25(2):161-71. PubMed ID: 18172786
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells.
Sugimoto T; Bartholomeusz C; Tari AM; Ueno NT
Breast Cancer Res; 2007; 9(4):R41. PubMed ID: 17612393
[TBL] [Abstract][Full Text] [Related]
12. Combination of EGFR and COX-2 inhibitors in breast cancer patient.
Wiwanitkit V
Tumour Biol; 2012 Aug; 33(4):1261. PubMed ID: 22362382
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
14. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
Torres-Arzayus MI; Yuan J; DellaGatta JL; Lane H; Kung AL; Brown M
Cancer Res; 2006 Dec; 66(23):11381-8. PubMed ID: 17145884
[TBL] [Abstract][Full Text] [Related]
15. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer.
Martin LA; Davies GL; Weigel MT; Betambeau N; Hills MJ; Salter J; Walsh G; A'Hern R; Dowsett M
Breast Cancer Res Treat; 2010 Oct; 123(3):829-36. PubMed ID: 20697803
[TBL] [Abstract][Full Text] [Related]
16. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.
Gee J; Lee IL; Jendiroba D; Fischer SM; Grossman HB; Sabichi AL
Oncol Rep; 2006 Feb; 15(2):471-7. PubMed ID: 16391871
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Park JS; Jun HJ; Cho MJ; Cho KH; Lee JS; Zo JI; Pyo H
Clin Cancer Res; 2006 Aug; 12(16):4989-99. PubMed ID: 16914589
[TBL] [Abstract][Full Text] [Related]
18. Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.
Kang KB; Zhu C; Yong SK; Gao Q; Wong MC
Mol Cancer; 2009 Aug; 8():66. PubMed ID: 19706164
[TBL] [Abstract][Full Text] [Related]
19. Combination effects of salvianolic acid B with low-dose celecoxib on inhibition of head and neck squamous cell carcinoma growth in vitro and in vivo.
Zhao Y; Hao Y; Ji H; Fang Y; Guo Y; Sha W; Zhou Y; Pang X; Southerland WM; Califano JA; Gu X
Cancer Prev Res (Phila); 2010 Jun; 3(6):787-96. PubMed ID: 20501859
[TBL] [Abstract][Full Text] [Related]
20. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells.
Cusimano A; Azzolina A; Iovanna JL; Bachvarov D; McCubrey JA; D'Alessandro N; Montalto G; Cervello M
Cell Cycle; 2010 Apr; 9(7):1399-410. PubMed ID: 20305374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
